Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Corporate updatesFor media and investors only
2025
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Financial updatesPharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”).
Pharming Group to participate in April investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Clinical trialsPharming Group N.V. announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation.
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming Group to participate in March investor conference
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of March:
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Financial updatesPharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent.
Pharming Group to participate in February investor conference
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of February: